BC-2027

N/A

Report date: 2026/05/21 20:00:22
First In Class

Base Information

Drug NameBC-2027
Drug Alias NameBC2027BC-2027
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionAnti-Glypican-3
TargetsGlypican-3
Therapy Area/IndicationsSolid tumoursLiver Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesWuxi BioCity
China Registration ClassN/A

Develop Information

Active CompaniesWuxi BioCity
Inactive CompaniesN/A
Active IndicationsSolid tumoursLiver Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A